Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Polaryx Therapeutics Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct art unit and 1 distinct examiner, indicating that the current prosecution activity is concentrated in one specialized review section. This focus allows the applicant to develop a targeted strategy that addresses the specific technical standards and legal interpretations of a single examiner group.
The busiest examiner for the portfolio is SAWYER, JENNIFER C, who is responsible for 1 pending office action. Because this examiner is the only one assigned to the current pending workload, their individual review tendencies will be the primary factor in the prosecution outcome. Practitioners should review the examiner's history in the Biotechnology & Pharmaceuticals field to prepare for the specific requirements of this pending matter. Understanding the examiner's typical approach to claim rejections or evidence requirements can help in formulating a more effective response to the pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAWYER, JENNIFER C | 1 | 68.4% | -8.2% |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17800498 | GEMFIBROZIL FORMULATION | SAWYER, JENNIFER C | 1691 | §103 | Non-Final OA | — | Pending | Aug 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPolaryx Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jennifer C Sawyer has the most, with 1 of Polaryx Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
